Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Regulatory T Cell Depletion Using A CRISPR Fc-Optimized CD25 Antibody

Version 1 : Received: 1 August 2022 / Approved: 2 August 2022 / Online: 2 August 2022 (08:10:26 CEST)

A peer-reviewed article of this Preprint also exists.

van Elsas, M.J.; van der Schoot, J.M.S.; Bartels, A.; Steuten, K.; van Dalen, D.; Wijfjes, Z.; Figdor, C.G.; van Hall, T.; van der Burg, S.H.; Verdoes, M.; Scheeren, F.A. Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. Int. J. Mol. Sci. 2022, 23, 8707. van Elsas, M.J.; van der Schoot, J.M.S.; Bartels, A.; Steuten, K.; van Dalen, D.; Wijfjes, Z.; Figdor, C.G.; van Hall, T.; van der Burg, S.H.; Verdoes, M.; Scheeren, F.A. Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody. Int. J. Mol. Sci. 2022, 23, 8707.

Journal reference: Int. J. Mol. Sci. 2022, 23, 8707
DOI: 10.3390/ijms23158707

Abstract

Regulatory T cells (Tregs) are major drivers behind immunosuppressive mechanisms and present a major hurdle for cancer therapy. Tregs are characterized by high expression of CD25, which is a potentially valuable target for Treg depletion to alleviate immune suppression. The preclinical anti-CD25 (αCD25) antibody, clone PC-61, has met with modest anti-tumor activity, due to its capacity to clear Tregs from circulation and lymph nodes but not those that reside in the tumor. Optimization of the Fc domain of this antibody clone has been shown to enhance intratumoral Treg depletion capacity. Here, we generated a stable cell line that produces optimized recombinant Treg depleting antibodies. A genome engineering strategy in which CRISPR-Cas9 was combined with homology directed repair (CRISPR-HDR) was utilized to optimize the Fc domain of the hybridoma PC-61 for effector functions by switching it from the original rat IgG1 to a mouse IgG2a isotype. In a syngeneic tumor mouse model the resulting αCD25-m2a antibody mediated effective depletion of tumor resident Tregs leading to a high effector T cell (Teff) to Treg ratio. Moreover, combination of the αCD25-m2a with αPD-L1 treatment augmented tumor eradication in mice, demonstrating the potential for αCD25 as a cancer immunotherapy.

Keywords

antibody; immunotherapy; CRISPR/HDR; FC optimization; hybridoma

Subject

LIFE SCIENCES, Immunology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.

We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.